FDA Clears Path for NRx Ketamine Approval with Only Packaging Certification Remaining — NRx Pharmaceuticals, Inc.

Event summary

FDA completed first-cycle review of NRx's preservative-free ketamine ANDA with no drug-related major deficiencies.
Remaining issue is packaging certification for a luer lock vial already used in three FDA-approved products (11.9M units shipped without issues).
FDA committed to reviewing the requested certification in the shortest possible review cycle following an August 6, 2026 clarification meeting.
NRx believes this outcome substantially de-risks the path to approval and commercialization.

The big picture

The FDA's first-cycle review clearance with no drug-related major deficiencies is a significant milestone for NRx, reducing regulatory risk in bringing its preservative-free ketamine to market. This approval comes at a critical time as ketamine faces shortages and increasing demand, aligning with broader public health efforts to strengthen U.S.-based supply of strategic medicines. The remaining packaging certification issue, while minor, highlights the FDA's focus on container closure systems in generic drug approvals.

What we're watching

Regulatory Speed: The pace at which FDA reviews the remaining packaging certification will determine the timeline for approval.
Commercialization Readiness: NRx's ability to scale production and distribution of preservative-free ketamine amid a national shortage.
Market Impact: How the approval of NRx's preservative-free ketamine affects the competitive landscape for mental health treatments.